Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
At Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz, clinical research in hematologic disease focuses on relapsed or refractory multiple myeloma. The trials are aimed at evaluating new treatment approaches that may help improve disease control and extend the time before progression.
- Testing a new therapy combination for multiple myeloma
- Assessing whether treatment can better delay disease progression
- Supporting improved outcomes for patients with hard-to-treat blood cancers
This area reflects a strong interest in advancing cancer treatment through studies that compare emerging options with established care.
Nutritional and Metabolic Diseases
Research in metabolic disease at this hospital includes studies in type 2 diabetes mellitus, with a particular focus on pediatric care. These trials are designed to examine whether new treatment options can improve blood sugar control and remain safe and well tolerated over time.
- Evaluating a therapy for type 2 diabetes
- Measuring changes in long-term glucose control
- Checking the safety and tolerability of a new diabetes treatment
The work supports better understanding of diabetes management in younger patients and helps inform future treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 16 therapeutic areas and 15 of 209 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 205 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1AstraZeneca AB4active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB16trials
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz
lock Showing 1 of 102 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 209 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 10 | Unknown | 2020-12-16 | 2025-03-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.